Last updated: September 8, 2026
Lutetium Lu-177 vipivotide tetraxetan, marketed by Novartis as Pluvicto, is one of the fastest-growing radioligand therapies in oncology. U.S. sales increased from approximately $271 million in 2022 to about $1.4 billion in 2024, driven by rising PSMA testing, expanded treatment capacity and broader physician adoption in metastatic castration-resistant prostate cancer (mCRPC). The principal commercial constraints are manufacturing scale, radiopharmaceutical logistics, nuclear-medicine capacity and patient eligibility rather than near-term generic competition.
What is lutetium Lu-177 vipivotide tetraxetan?
Lutetium Lu-177 vipivotide tetraxetan is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy. The molecule binds PSMA-expressing prostate cancer cells and delivers beta radiation from lutetium-177.
Novartis markets the drug in the United States under the brand name Pluvicto. Its principal use is PSMA-positive metastatic castration-resistant prostate cancer after prior androgen-receptor pathway inhibitor therapy and taxane-based chemotherapy, subject to the applicable FDA label.
The product combines:
| Component |
Function |
| PSMA-binding ligand |
Directs the drug to PSMA-expressing tumor cells |
| Linker |
Connects the targeting ligand to the radionuclide |
| Lutetium-177 |
Emits therapeutic beta radiation |
| Imaging companion |
PSMA PET imaging identifies eligible patients |
Pluvicto is administered intravenously in specialized nuclear-medicine or radiopharmaceutical centers. The product requires radiation-safety procedures, dosimetry management, renal monitoring and a controlled supply chain.
What is the FDA regulatory status of Pluvicto?
The FDA granted accelerated approval to Pluvicto in March 2022 for adults with PSMA-positive mCRPC who had previously received androgen-receptor pathway inhibition and taxane chemotherapy. The approval was based primarily on the VISION trial, which showed improved radiographic progression-free survival and overall survival compared with standard care alone (FDA, 2022; Sartor et al., 2021).
The VISION trial reported:
| Endpoint |
Pluvicto plus standard care |
Standard care |
| Median overall survival |
15.3 months |
11.3 months |
| Median radiographic progression-free survival |
8.7 months |
3.4 months |
| Overall survival hazard ratio |
0.62 |
Reference |
| Radiographic progression-free survival hazard ratio |
0.40 |
Reference |
In March 2025, the FDA expanded the indication to patients with PSMA-positive mCRPC previously treated with an androgen-receptor pathway inhibitor when delaying taxane chemotherapy is clinically appropriate. This materially increased the addressable market by moving Pluvicto into an earlier treatment setting (FDA, 2025).
The FDA label requires PSMA PET-based patient selection. The most important approved imaging pathway uses gallium-68 gozetotide, marketed by Novartis as Locametz, although other approved PSMA imaging agents may be relevant depending on the regulatory setting.
When does Pluvicto lose exclusivity?
Pluvicto has several layers of protection, including regulatory exclusivity, chemical and formulation patents, radioligand manufacturing know-how, device and packaging rights, method-of-use patents, trademarks and a complex radiation-isotope supply chain.
The principal commercial protection periods are:
| Protection category |
Key consideration |
| U.S. approval |
March 2022 initial approval |
| Accelerated-approval risk |
Confirmatory evidence was required under the original approval pathway |
| New indication exclusivity |
The 2025 earlier-line indication may receive separate regulatory protection under applicable FDA rules |
| Orphan-drug protection |
The mCRPC indication is not generally treated as an orphan indication with seven-year exclusivity |
| Patent estate |
Includes composition, conjugate, formulation, therapeutic-use and manufacturing claims |
| Generic entry |
Likely requires a complex Abbreviated New Drug Application or other applicable pathway, with substantial radiopharmaceutical manufacturing capability |
The exact generic-entry date cannot be determined from the FDA approval date alone. It depends on the currently listed Orange Book patents, patent-term adjustments, patent-term extension, pediatric exclusivity, Paragraph IV litigation and any settlement agreements.
What patents protect lutetium Lu-177 vipivotide tetraxetan?
The patent estate is expected to include claims directed to:
- The PSMA-binding ligand and radiometal conjugate.
- Lutetium-177 complexes and pharmaceutical compositions.
- Radiolabeling and purification processes.
- Dosing regimens for PSMA-positive prostate cancer.
- Patient selection based on PSMA imaging.
- Combination treatment with androgen-receptor pathway inhibitors or other therapies.
- Manufacturing, kits, containers and radiopharmaceutical delivery systems.
The strongest barriers are likely to be the composition and radioligand manufacturing claims. Method-of-use patents may extend commercial protection after core chemical patents expire, but their practical value depends on claim scope and the ability to prove infringement from treatment records.
The FDA Orange Book is the controlling source for patents listed against the approved drug product. Pluvicto’s listing should be reviewed against the current edition of Approved Drug Products with Therapeutic Equivalence Evaluations before making a launch or litigation decision (FDA, 2025b). A complete patent expiration analysis requires matching each listed patent to its patent-term adjustment, patent-term extension and any pediatric exclusivity.
How strong is the Pluvicto patent estate?
The estate is commercially strong but operationally more complex than a conventional small-molecule drug patent estate.
Chemical and formulation protection
Chemical claims can block direct copies of the exact radioligand or closely related pharmaceutical compositions. Their strength depends on claim breadth, written-description support and the ability of a challenger to design around the claimed ligand, linker or chelator.
Formulation claims can protect stability, radiolabeling conditions, radionuclide concentration, excipients and storage requirements. These claims may be important because lutetium-177 products have limited shelf lives and require validated handling procedures.
Method-of-use protection
Use claims can cover PSMA-positive mCRPC, particular lines of therapy, patient selection and dose schedules. The 2025 earlier-line approval creates an important commercial opportunity for method-of-use protection because patients are being treated before taxane chemotherapy.
Manufacturing barriers
Manufacturing claims and trade secrets may be more important than patent expiration in the near term. A competitor needs access to:
- Medical-grade lutetium-177.
- A validated PSMA ligand and radiolabeling process.
- Good manufacturing practice production.
- Radiation-shielded facilities.
- Radioactive-material licenses.
- Dose-calibration and quality-control systems.
- Time-sensitive distribution infrastructure.
These requirements raise entry costs and reduce the likelihood of immediate price erosion after the first patent expiry.
How large is the Pluvicto market?
The market expanded rapidly after launch.
| Fiscal year |
Approximate Pluvicto sales |
Commercial status |
| 2022 |
$271 million |
Partial-year launch |
| 2023 |
$980 million |
Broadening U.S. and international uptake |
| 2024 |
Approximately $1.4 billion |
Capacity expansion and growing treatment volumes |
Source: Novartis annual reports and financial disclosures (Novartis, 2023, 2024, 2025).
The revenue trajectory reflects more than patient demand. It also reflects the number of hospitals able to administer radioligand therapy, the availability of PSMA PET imaging, referral patterns from community oncology, reimbursement and the supply of lutetium-177.
The 2025 earlier-line FDA approval has the potential to expand the eligible U.S. population materially. The initial label required prior taxane exposure, which limited treatment to later-line patients. Earlier use can increase treatment duration, improve physician adoption and reduce the proportion of patients who deteriorate before receiving radioligand therapy.
What drives Pluvicto revenue growth?
Earlier-line treatment
The largest growth driver is movement into earlier mCRPC treatment. Patients treated before chemotherapy may have better performance status, greater treatment persistence and a higher probability of completing multiple cycles.
Manufacturing expansion
Novartis has invested in radioligand production and distribution capacity. The company has expanded facilities and supply arrangements to address production constraints that affected the broader radioligand market.
International rollout
The commercial opportunity extends across Europe, Japan and other markets with PSMA imaging infrastructure and reimbursement pathways. Launch timing varies because each jurisdiction applies separate regulatory, pricing and nuclear-material rules.
PSMA imaging penetration
Every Pluvicto patient generally requires imaging-based confirmation of PSMA expression. Greater use of PSMA PET increases the diagnosable treatment population, but imaging capacity can constrain demand.
Treatment-center expansion
A larger network of qualified hospitals reduces travel burdens and improves referral conversion. Community-oncology partnerships may become important as the product moves earlier in the treatment sequence.
Which companies are challenging Pluvicto?
Competition is developing across three categories: radioligand therapy, PSMA-targeted nonradioactive therapies and conventional mCRPC treatments.
| Company or product |
Competitive position |
| Novartis Pluvicto |
Marketed PSMA-targeted radioligand therapy |
| Novartis Lutathera |
Established radioligand infrastructure and manufacturing experience |
| POINT Biopharma |
PSMA and other radioligand programs acquired by Lilly |
| Eli Lilly |
Radioligand pipeline following acquisition of POINT Biopharma |
| RayzeBio |
Radiopharmaceutical platform acquired by Bristol Myers Squibb |
| Bristol Myers Squibb |
Radioligand and targeted oncology development |
| ITM Isotope Technologies |
Lutetium-based radiopharmaceutical development |
| Orano Med |
Alpha-emitting radioligand programs |
| Clarity Pharmaceuticals |
Copper-based targeted radiopharmaceutical programs |
| Telix Pharmaceuticals |
PSMA imaging and therapeutic radiopharmaceutical programs |
The most direct competitors are other PSMA-targeted therapies. Products using alpha emitters may offer different radiation properties, while nonradioactive PSMA-targeted agents could compete for the same patient population without requiring nuclear-medicine administration.
What generic entry risks exist for Pluvicto?
Near-term generic risk is low relative to conventional oral oncology products. A competitor must replicate more than the active ingredient. It must establish radionuclide supply, radiochemical purity, sterility, stability, release testing, distribution and treatment-center delivery.
The principal entry scenarios are:
| Scenario |
Likely commercial effect |
| No early Paragraph IV challenger |
Continued Novartis pricing power |
| Paragraph IV challenge to a core composition patent |
Litigation and possible settlement |
| Later challenge to formulation or method patents |
Narrower launch risk |
| Authorized generic or licensed radioligand |
Controlled price competition |
| Competing PSMA radioligand |
Share erosion without direct patent invalidation |
| Alpha-emitting entrant |
Clinical differentiation and possible premium pricing |
| Manufacturing disruption |
Revenue loss even without competitive entry |
A generic or biosimilar framework does not map neatly onto Pluvicto. It is a chemically defined radiopharmaceutical, not a biologic, but its radioactive component and complex manufacturing process create regulatory issues beyond a standard small-molecule tablet.
What is the Paragraph IV and litigation status?
No major publicly established Paragraph IV litigation outcome should be assumed without a current review of the FDA Orange Book, ANDA filings and PACER or district-court records. The commercial risk is more likely to emerge first through competing radioligand products, patent oppositions, licensing transactions or challenges to individual method-of-use claims than through a near-term conventional generic launch.
Potential litigation issues include:
- Validity of broad PSMA-ligand claims.
- Obviousness of radiolabeling and chelation chemistry.
- Written description and enablement of broad genus claims.
- Infringement of manufacturing-process claims.
- Induced infringement of method-of-use claims.
- Patent-term calculations.
- FDA labeling carve-outs for treatment-line restrictions.
- Ownership of university or biotechnology-originated inventions.
Does Pluvicto face biosimilar risk?
No conventional biosimilar risk applies because Pluvicto is a defined radioligand drug rather than a protein biologic. The relevant threats are generic radiopharmaceuticals, follow-on radioligand products and clinically differentiated PSMA therapies.
The absence of biosimilar competition does not eliminate price risk. Competing PSMA agents may reduce the product’s market share, particularly if they offer improved safety, fewer administrations, more favorable logistics or access to earlier-line patients.
How does Pluvicto compare with competing prostate-cancer drugs?
Pluvicto occupies a later-line and increasingly earlier-line position in mCRPC. It differs from oral androgen-receptor pathway inhibitors, chemotherapy and targeted DNA-repair therapies because it requires PSMA imaging and radioactive drug administration.
| Therapy class |
Administration |
Patient selection |
Main commercial strength |
| Pluvicto |
Intravenous radioligand |
PSMA PET positive |
Targeted radiation and survival benefit |
| Androgen-receptor pathway inhibitor |
Oral |
Molecular and clinical criteria |
Broad outpatient use |
| Taxane chemotherapy |
Intravenous |
Clinical status and prior therapy |
Established treatment infrastructure |
| PARP inhibitor |
Oral |
DNA-repair biomarker in relevant populations |
Biomarker-driven use |
| PSMA imaging agent |
Intravenous diagnostic |
Suspected or known PSMA-positive disease |
Enables patient selection |
Pluvicto’s commercial advantage is its differentiated mechanism and demonstrated survival benefit. Its disadvantages include facility requirements, radiation handling, renal and hematologic monitoring and dependence on PSMA-positive disease.
What is the financial outlook for Pluvicto?
The base-case financial outlook remains positive. Revenue growth should continue as the earlier-line indication increases the eligible population and as Novartis expands production and treatment-center access.
The main variables are:
- The rate of uptake in pre-taxane mCRPC.
- Manufacturing capacity and radionuclide availability.
- Reimbursement for PSMA PET and radioligand administration.
- Treatment completion rates.
- Competition from alpha-emitting and nonradioactive PSMA therapies.
- Patent litigation and settlement timing.
- International price controls.
- Long-term safety and sequencing data.
The product could become a multibillion-dollar franchise if earlier-line adoption proceeds across major markets. Revenue concentration remains significant because Pluvicto is an individual branded product with high technical and regulatory requirements. Supply interruptions could create a direct financial impact even when clinical demand remains strong.
What licensing deals affect the Pluvicto market?
Pluvicto’s commercial position is linked to Novartis’s broader radioligand platform, including internal manufacturing and external technology relationships. The company’s radioligand strategy has included acquisitions, licensing and supply agreements across isotope production, ligand chemistry, manufacturing and delivery.
Competitors have also used licensing and acquisitions to secure radiopharmaceutical technology. Eli Lilly’s acquisition of POINT Biopharma and Bristol Myers Squibb’s acquisition of RayzeBio increased the strategic value of PSMA ligands, alpha emitters and radioligand manufacturing platforms.
The key transaction risk is platform access. A company may hold a clinically promising ligand but lack isotope supply, manufacturing sites or distribution capacity. Conversely, isotope suppliers and contract manufacturers can gain bargaining power as radioligand demand increases.
Key Takeaways
- Pluvicto is Novartis’s lutetium-177 PSMA-targeted radioligand for prostate cancer.
- Sales rose from about $271 million in 2022 to approximately $1.4 billion in 2024.
- The 2025 FDA expansion into earlier-line mCRPC materially increases the addressable market.
- Manufacturing, isotope supply, imaging access and treatment-center capacity are major commercial constraints.
- Near-term biosimilar risk is not applicable; the main threats are competing radioligands and complex generic entry.
- The patent estate likely covers composition, formulation, use, imaging-based selection and manufacturing.
- Orange Book patents, patent-term adjustments, pediatric exclusivity and Paragraph IV activity determine the actual U.S. launch date.
- The strongest competitive risk comes from differentiated PSMA radioligands, alpha-emitting agents and nonradioactive PSMA therapies.
- Pluvicto has a credible multibillion-dollar revenue path if earlier-line adoption and manufacturing expansion proceed without major supply disruption.
FAQs
Is lutetium Lu-177 vipivotide tetraxetan the same as Pluvicto?
Yes. Lutetium Lu-177 vipivotide tetraxetan is the nonproprietary name, and Pluvicto is the Novartis brand.
What cancer does Pluvicto treat?
It treats PSMA-positive metastatic castration-resistant prostate cancer under the FDA-approved indications.
Does Pluvicto require a companion diagnostic?
Patient selection requires PSMA PET imaging to confirm sufficient PSMA expression for treatment.
Why is Pluvicto difficult to manufacture?
It requires radioactive lutetium-177, validated radiolabeling, sterile production, radiation-shielded facilities, specialized quality controls and time-sensitive distribution.
Will Pluvicto face generic competition after patent expiry?
Generic competition is possible, but entry may be delayed by radiopharmaceutical manufacturing requirements, isotope supply, regulatory complexity and method-of-use or manufacturing patents.
References
- U.S. Food and Drug Administration. (2022). FDA approves Pluvicto for metastatic castration-resistant prostate cancer. https://www.fda.gov
- U.S. Food and Drug Administration. (2025a). FDA approves Pluvicto for earlier treatment of metastatic castration-resistant prostate cancer. https://www.fda.gov
- U.S. Food and Drug Administration. (2025b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
- Novartis. (2023). Annual report 2022. https://www.novartis.com
- Novartis. (2024). Annual report 2023. https://www.novartis.com
- Novartis. (2025). Annual report 2024. https://www.novartis.com
- Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., et al. (2021). Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322
